Business Context and Reporting Period
Company: ChromaDex Corporation (Note: Input metadata referenced "Niagen Bioscience," but the filing text identifies the registrant as ChromaDex Corporation).
Filing Type: Form 10-Q (Quarterly Report).
Reporting Period: Three months ended April 4, 2009.
Business Overview: ChromaDex creates and supplies botanical reference standards, phytochemical products, and related services for the functional food, pharmaceutical, personal care, and dietary supplement markets. The company operates as a smaller reporting company and is not a shell company.
Key Financial Metrics
| Metric | Q1 2009 (Ended Apr 4) | Q1 2008 (Ended Mar 29) |
|---|---|---|
| Net Sales | $1,447,127 | $1,059,716 |
| Gross Profit | $468,073 | $399,444 |
| Gross Margin | 32.3% | 37.7% |
| Operating Loss | $(320,192) | $(115,694) |
| Net Loss | $(323,842) | $(122,906) |
| Loss Per Share (Basic & Diluted) | $(0.01) | $(0.00) |
| Cash and Equivalents (Ending) | $842,988 | $1,694,661 |
| Net Cash Used in Operating Activities | $(251,311) | $(362,635) |
| Total Current Liabilities | $2,162,957 | $2,073,331 |
| Accumulated Deficit | $(7,523,800) | $(7,199,958) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 37% year-over-year, driven by additional service offerings and increased demand for existing products.
- Expense Increases:
- Cost of Goods Sold (COGS): Increased 48% to $979,054. As a percentage of sales, COGS rose 5% due to fixed labor/overhead costs and higher raw material costs for high-volume products.
- General and Administrative (G&A): Increased 65% to $566,643, primarily due to costs associated with public company compliance (legal, accounting, insurance) and executive salaries.
- Selling Expenses: Increased 29% to $221,622 due to expanded advertising and sales staff.
- Widened Loss: Net loss more than doubled from $122,906 in Q1 2008 to $323,842 in Q1 2009, reflecting the significant rise in operating expenses outpacing revenue growth.
- Cash Position: Cash decreased by $282,516 during the quarter. Unlike the prior year, there were no proceeds from stock issuance in Q1 2009.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current capital is sufficient to fund operations for the next ten months. However, the company may require additional financing to implement its long-term business plan. There is no assurance that financing will be available on favorable terms.
- Strategic Focus: The company is targeting growth based on upcoming FDA Good Manufacturing Practices (GMP) guidelines for the dietary supplement industry and trends toward "green chemistry." Plans include expanding service capacity, implementing accreditation programs, and potentially establishing a GMP-compliant pilot plant.
- Risks and Contingencies:
- Financing Risk: Inability to raise additional capital could force the company to delay product expansion or curtail operations.
- Regulatory Risk: Uncertainty regarding the extent of FDA enforcement of new GMP regulations could materially impact demand for ChromaDex's compliance-related products.
- Production Risk: Failure to establish small-to-medium scale production capabilities internally or through collaboration could result in lost revenue streams.
- Unusual Items: The filing notes a significant increase in stock-based compensation expense ($46,962 in Q1 2009 vs. $184 in Q1 2008) due to the granting of 355,000 options.
Investor Verification Checklist
- Verify the sufficiency of the $842,988 cash balance to cover the projected ten-month runway given the current burn rate of approximately $250,000 per quarter in operating cash flow.
- Confirm the timeline and potential impact of FDA GMP regulation enforcement on the dietary supplement market demand.
- Review the terms of the $1.18 million "Due to officers" liability on the balance sheet to understand repayment obligations and related party risks.
- Assess the company's ability to secure additional financing if the ten-month capital runway is exhausted before profitability is achieved.
- Monitor the execution of the plan to establish a GMP-compliant pilot plant or secure a collaboration partner for production capabilities.